
Roberto Chiarle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7930265/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer, 2008, 8, 11-23.	12.8	792
2	Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell, 2011, 147, 107-119.	13.5	411
3	Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nature Methods, 2013, 10, 361-365.	9.0	409
4	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine, 2005, 11, 623-629.	15.2	406
5	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene, 2002, 21, 1038-1047.	2.6	354
6	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma InÂVivo. Cell, 2015, 161, 319-332.	13.5	293
7	Role of the F-box protein Skp2 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 2515-2520.	3.3	269
8	FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature, 2012, 481, 90-93.	13.7	256
9	NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101, 1919-1927.	0.6	234
10	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	13.5	220
11	The STAT3 isoforms \hat{I}_{\pm} and \hat{I}^2 have unique and specific functions. Nature Immunology, 2004, 5, 401-409.	7.0	202
12	Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 2000, 95, 619-626.	0.6	199
13	Simple and Rapid InÂVivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology. Cell Reports, 2014, 9, 1219-1227.	2.9	186
14	Substitutions at Codon 22 of Alzheimer's AÎ ² Peptide Induce Diverse Conformational Changes and Apoptotic Effects in Human Cerebral Endothelial Cells. Journal of Biological Chemistry, 2000, 275, 27110-27116.	1.6	178
15	CD30 in Normal and Neoplastic Cells. Clinical Immunology, 1999, 90, 157-164.	1.4	158
16	Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes. Journal of Clinical Investigation, 2006, 116, 3171-3182.	3.9	139
17	Mechanisms that Promote and Suppress Chromosomal Translocations in Lymphocytes. Annual Review of Immunology, 2011, 29, 319-350.	9.5	137
18	Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood, 2006, 107, 689-697.	0.6	127

#	Article	IF	CITATIONS
19	An integrated humoral and cellular response is elicited in pancreatic cancer by αâ€enolase, a novel pancreatic ductal adenocarcinomaâ€associated antigen. International Journal of Cancer, 2009, 125, 639-648.	2.3	115
20	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nature Medicine, 2008, 14, 676-680.	15.2	112
21	New and Old Functions of STAT3: A Pivitol Target for Individualized Treatment of Cancer. Cell Cycle, 2005, 4, 1131-1133.	1.3	111
22	MT1-MMP Is Required for Myeloid Cell Fusion via Regulation of Rac1 Signaling. Developmental Cell, 2010, 18, 77-89.	3.1	108
23	The Role of Mechanistic Factors in Promoting Chromosomal Translocations Found in Lymphoid and Other Cancers. Advances in Immunology, 2010, 106, 93-133.	1.1	106
24	Phosphatidylinositol 3-kinase l´ blockade increases genomic instability in B cells. Nature, 2017, 542, 489-493.	13.7	105
25	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. Gastroenterology, 2013, 144, 1098-1106.	0.6	104
26	S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase. American Journal of Pathology, 2002, 160, 1457-1466.	1.9	94
27	Autoantibody Signature in Human Ductal Pancreatic Adenocarcinoma. Journal of Proteome Research, 2007, 6, 4025-4031.	1.8	88
28	The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. Cancer Research, 2007, 67, 4278-4286.	0.4	86
29	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. Cancer Research, 2009, 69, 8611-8619.	0.4	86
30	A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature, 2017, 548, 239-243.	13.7	85
31	Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clinical and Experimental Immunology, 2007, 149, 504-512.	1.1	83
32	The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Research, 2000, 3, 91.	2.2	79
33	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers, 2018, 10, 62.	1.7	73
34	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood, 2005, 106, 3907-3916.	0.6	72
35	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function. Cancer Cell, 2017, 32, 444-459.e7.	7.7	69
36	Anaplastic large cell lymphoma: one or more entities among Tâ€cell lymphoma?. Hematological Oncology, 2009, 27, 161-170.	0.8	61

#	Article	IF	CITATIONS
37	Detection of Immunoglobulin l̂º Light Chain Rearrangements by Polymerase Chain Reaction. American Journal of Pathology, 1999, 155, 355-363.	1.9	60
38	The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. Journal of Cell Science, 2007, 120, 1859-1867.	1.2	59
39	Leukocyte transmigration is modulated by chemokineâ€mediated PI3Kγâ€dependent phosphorylation of vimentin. European Journal of Immunology, 2009, 39, 1136-1146.	1.6	59
40	Advances in cancer immunology and cancer immunotherapy. Discovery Medicine, 2016, 21, 125-33.	0.5	58
41	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase l³. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14354-14359.	3.3	57
42	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. Molecular Therapy, 2011, 19, 2201-2212.	3.7	57
43	Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nature Communications, 2016, 7, 10934.	5.8	57
44	Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature Medicine, 2019, 25, 130-140.	15.2	57
45	Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. Molecular Therapy, 2011, 19, 1131-1140.	3.7	56
46	The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation. Cancer Research, 2008, 68, 8899-8907.	0.4	54
47	In Vivo Interference with Skp1 Function Leads to Genetic Instability and Neoplastic Transformation. Molecular and Cellular Biology, 2002, 22, 8375-8387.	1.1	53
48	A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 741-750.	1.7	51
49	Heat shock protein expression in diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2008, 295, F1817-F1824.	1.3	50
50	Estrogen Receptor α Is a Novel Marker Expressed by Follicular Dendritic Cells in Lymph Nodes and Tumor-Associated Lymphoid Infiltrates. American Journal of Pathology, 2003, 163, 1313-1320.	1.9	49
51	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. Cancer Research, 2014, 74, 6094-6106.	0.4	45
52	STAT3 activity is necessary and sufficient for the development of immuneâ€mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Molecular Medicine, 2013, 5, 572-590.	3.3	44
53	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. Neoplasia, 2013, 15, 511-IN17.	2.3	44
54	Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1. Clinical Immunology, 2017, 183, 142-144.	1.4	43

#	Article	IF	CITATIONS
55	Role of Pax2 in Apoptosis Resistance and Proinvasive Phenotype of Kaposi's Sarcoma Cells. Journal of Biological Chemistry, 2004, 279, 4136-4143.	1.6	42
56	IL-18 Paradox in Pancreatic Carcinoma: Elevated Serum Levels of Free IL-18 are Correlated With Poor Survival. Journal of Immunotherapy, 2009, 32, 920-931.	1.2	42
57	The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood, 2009, 113, 2776-2790.	0.6	42
58	Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. Journal of Hematology and Oncology, 2013, 6, 67.	6.9	42
59	Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343.	1.6	42
60	Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Frontiers in Bioscience - Landmark, 2008, Volume, 6501.	3.0	41
61	PHOX2B-Mediated Regulation of ALK Expression: In Vitro Identification of a Functional Relationship between Two Genes Involved in Neuroblastoma. PLoS ONE, 2010, 5, e13108.	1.1	40
62	FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells. Cell Reports, 2014, 6, 18-23.	2.9	39
63	Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E327-E336.	3.3	39
64	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, 2016, 35, 3854-3865.	2.6	37
65	Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget, 2016, 7, 33316-33330.	0.8	35
66	RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Therapy, 2005, 12, 456-463.	2.2	34
67	Tissue flow cytometry immunophenotyping in the diagnosis and classification of nonâ€Hodgkin's lymphomas: A retrospective evaluation of 1,792 cases. Cytometry Part B - Clinical Cytometry, 2013, 84B, 82-95.	0.7	33
68	<i>IgH</i> class switching exploits a general property of two DNA breaks to be joined <i>in cis</i> over long chromosomal distances. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 2644-2649.	3.3	33
69	Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: A tissue micro array-based multicenter study. Lung Cancer, 2014, 85, 191-196.	0.9	32
70	IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia, 2009, 23, 2102-2108.	3.3	31
71	Detection ofBCL-6 rearrangements andp53 mutations in malt-lymphomas. , 1997, 56, 206-213.		30
72	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. Cancer Research, 2014, 74, 5978-5988.	0.4	30

#	Article	IF	CITATIONS
73	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Research, 2016, 76, 6095-6106.	0.4	30
74	Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. Nature Communications, 2022, 13, .	5.8	30
75	Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 350-355.	1.4	29
76	Stat3 is required for anchorageâ€independent growth and metastasis but not for mammary tumor development downstream of the ErbBâ€2 oncogene. Molecular Carcinogenesis, 2010, 49, 114-120.	1.3	29
77	Long-term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity. American Journal of Surgical Pathology, 1995, 19, 918-926.	2.1	28
78	The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis, 2013, 2, e43-e43.	2.1	27
79	IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	27
80	Pure Alveolar Rhabdomyosarcoma of the Corpus Uteri: Description of a Case with Increased Serum Level of CA-125. Gynecologic Oncology, 1997, 66, 320-323.	0.6	26
81	Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood, 2016, 127, 1297-1306.	0.6	26
82	RHO Family GTPases in the Biology of Lymphoma. Cells, 2019, 8, 646.	1.8	26
83	Incestuous Paternity Detected by STR-typing of Chorionic Villi Isolated from Archival Formalin-fixed Paraffin-embedded Abortion Material Using Laser Microdissection. Journal of Forensic Sciences, 2006, 51, 90-92.	0.9	25
84	Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth. Journal of Biological Chemistry, 2010, 285, 26441-26450.	1.6	25
85	Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy. Journal of Biological Chemistry, 2007, 282, 6812-6822.	1.6	24
86	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget, 2017, 8, 18680-18698.	0.8	24
87	Dissecting ELANE neutropenia pathogenicity by human HSC gene editing. Cell Stem Cell, 2021, 28, 833-845.e5.	5.2	23
88	Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer, 1994, 74, 1568-1574.	2.0	22
89	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood, 2011, 117, 6617-6626.	0.6	22
90	IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 1657-1669.	0.6	22

#	Article	IF	CITATIONS
91	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood, 2022, 139, 717-731.	0.6	22
92	Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein ΔBRCA1(17aa). Oncogene, 2000, 19, 2767-2773.	2.6	20
93	In the absence of IGF-1 signaling, IFN-Î ³ suppresses human malignant T-cell growth. Blood, 2007, 109, 2496-2504.	0.6	20
94	Developmentallyâ€faithful and effective human erythropoiesis in immunodeficient and <i>Kit</i> mutant mice. American Journal of Hematology, 2017, 92, E513-E519.	2.0	20
95	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. British Journal of Haematology, 2000, 111, 263-271.	1.2	19
96	Follicular Origin of a Subset of CD5+ Diffuse Large B-Cell Lymphomas. American Journal of Clinical Pathology, 2005, 124, 182-190.	0.4	18
97	CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation. Cell Reports, 2019, 28, 1307-1322.e8.	2.9	18
98	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leukemia and Lymphoma, 2011, 52, 1742-1750.	0.6	17
99	Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer. Oncotarget, 2017, 8, 92265-92274.	0.8	17
100	An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors. Clinical Cancer Research, 2008, 14, 2220-2226.	3.2	15
101	The battle against ALK resistance: successes and setbacks. Expert Opinion on Investigational Drugs, 2012, 21, 1751-1754.	1.9	15
102	STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. American Journal of Cancer Research, 2014, 4, 484-94.	1.4	14
103	Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. Blood, 2022, 139, 2534-2546.	0.6	14
104	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget, 2017, 8, 3274-3288.	0.8	13
105	p53 expression and proliferative activity predict survival in non-invasive thymomas. , 1996, 69, 180-183.		12
106	High Energy Shock Waves (HESW) Increase Paclitaxel Efficacy in a Syngeneic Model of Breast Cancer. Technology in Cancer Research and Treatment, 2008, 7, 117-124.	0.8	12
107	Expression of IFNÎ ³ R2 mutated in a dileucine internalization motif reinstates IFNÎ ³ signaling and apoptosis in human T lymphocytes. Immunology Letters, 2010, 134, 17-25.	1.1	12
108	Primary Cutaneous Bâ€Cell Lymphoblastic Lymphoma Arising from a Long‣tanding Lesion in a Child and Review of the Literature. Pediatric Dermatology, 2017, 34, e182-e186.	0.5	12

#	Article	IF	CITATIONS
109	The CRISPR/Cas9 System as a Tool to Engineer Chromosomal Translocation In Vivo. Advances in Experimental Medicine and Biology, 2018, 1044, 39-48.	0.8	12
110	Identification of the Same HRAS1 Mutation in a Primary Minimally Invasive Follicular Carcinoma of the Thyroid Gland and its Bone Metastasis Developed 15 Years Later. Diagnostic Molecular Pathology, 1995, 4, 73-74–74.	2.1	11
111	Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer Journal, 2014, 4, e249-e249.	2.8	11
112	Parp3 promotes long-range end joining in murine cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10076-10081.	3.3	11
113	Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer, 2020, 146, 366-369.	0.9	11
114	Anaplastic lymphoma kinase: an oncogene for tumor vaccination. Journal of Molecular Medicine, 2009, 87, 669-677.	1.7	10
115	High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. Cancers, 2020, 12, 2951.	1.7	8
116	CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma. Blood, 2021, 138, 2276-2276.	0.6	8
117	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	0.6	8
118	Translocations in Normal B Cells and Cancers. Advances in Immunology, 2013, 117, 39-71.	1.1	7
119	Comment on "ALK is a therapeutic target for lethal sepsis― Science Translational Medicine, 2018, 10, .	5.8	7
120	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. Blood Advances, 2021, 5, 5239-5257.	2.5	7
121	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines, 2017, 5, 20.	2.1	6
122	The anaplastic lymphoma kinase as an oncogene in solid tumors. Frontiers in Bioscience - Scholar, 2015, 7, 269-282.	0.8	5
123	Solving the chromosome puzzle of aneuploidy in cancer. Genes and Development, 2021, 35, 1073-1075.	2.7	5
124	Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. American Journal of Clinical Pathology, 2005, 124, 182-90.	0.4	5
125	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. ELife, 2016, 5, .	2.8	5
126	CALming Down T Cell Acute Leukemia. Cancer Cell, 2012, 21, 449-450.	7.7	4

8

#	Article	IF	CITATIONS
127	Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells. Cell, 2011, 147, 1640.	13.5	3
128	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. , 0,		3
129	Deletion of murine <i>Rhoh</i> leads to de-repression of <i>Bcl-6</i> via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma. Small GTPases, 2022, 13, 267-281.	0.7	3
130	The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA. Blood, 2014, 124, 263-263.	0.6	2
131	Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Advances, 2022, 6, 2893-2896.	2.5	2
132	A LIBRETTO to orchestrate targeted therapy. Nature Cancer, 2020, 1, 1038-1040.	5.7	1
133	Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clinic Proceedings, 2021, 96, 817.	1.4	1
134	p53 Overexpression and Thymoma Prognosis. , 1997, , 47-54.		1
135	PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression. Blood, 2015, 126, 164-164.	0.6	1
136	P3.02a-006 Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1162-S1163.	0.5	0
137	Abstract 1544: Generation of ALK CAR-T cells for neuroblastoma therapy. , 2021, , .		0
138	FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma. Blood, 2015, 126, 3673-3673.	0.6	0
139	De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC). Blood, 2015, 126, 2650-2650.	0.6	0
140	Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP. Blood, 2016, 128, 5305-5305.	0.6	0
141	CRISPR/Cas9 Screens Reveal Multiple Layers of B Cell CD40 Regulation. SSRN Electronic Journal, 0, , .	0.4	0
142	Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma. Blood, 2019, 134, 5060-5060.	0.6	0